Refractory Multiple Myeloma - Pipeline Review, H2 2015 Now Available at iData Insights Refractory Multiple Myeloma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Refractory Multiple Myeloma - Pipeline Review, H2 2015 , provides an overview of the Refractory Multiple Myeloma s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Global Markets Direct s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Multiple Myeloma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Multiple Myeloma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landingpage.php?id=124191/refractory-multiple-myeloma-pipeline-review-h2-2015 To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=124191/refractory-multiple-myeloma-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Refractory Multiple Myeloma Overview
1
10 Therapeutics Development 11 Pipeline Products for Refractory Multiple Myeloma - Overview 11 Pipeline Products for Refractory Multiple Myeloma - Comparative Analysis 12 Refractory Multiple Myeloma - Therapeutics under Development by Companies 13 Refractory Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes 18 Refractory Multiple Myeloma - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Refractory Multiple Myeloma - Products under Development by Companies 22 Refractory Multiple Myeloma - Products under Investigation by Universities/Institutes 27 Refractory Multiple Myeloma - Companies Involved in Therapeutics Development 28 4SC AG 28 AbbVie Inc. 29 Acetylon Pharmaceuticals, Inc. 30 Altor BioScience Corporation 31 Arno Therapeutics, Inc. 32 Array BioPharma Inc. 33 Astellas Pharma Inc. 34 Astex Pharmaceuticals, Inc. 35 Biotest AG 36 Boehringer Ingelheim GmbH 37 Bristol-Myers Squibb Company 38 Calithera Biosciences, Inc. 39 Celgene Corporation 40 Cellectar Biosciences, Inc. 41 Cleave Biosciences 42 CureTech Ltd. 43 Curis, Inc. 44 Dicerna Pharmaceuticals, Inc. 45 Exelixis, Inc. 46 F. Hoffmann-La Roche Ltd. 47 GlaxoSmithKline Plc
2
48 Immunomedics, Inc. 49 Jasco Pharmaceuticals, LLC. 50 Johnson & Johnson 51 JW Pharmaceutical Corporation 52 Karyopharm Therapeutics, Inc. 53 MedImmune, LLC 54 Merck & Co., Inc. 55 Millennium Pharmaceuticals, Inc. 56 MorphoSys AG 57 Novartis AG 58 Oncolytics Biotech Inc. 59 Oncopeptides AB 60 Onyx Pharmaceuticals, Inc. 61 Otsuka Holdings Co., Ltd. 62 Patrys Limited 63 Pfizer Inc. 64 Pharma Mar, S.A. 65 Prolexys Pharmaceuticals, Inc. 66 Sanofi 67 Sigma-Tau S.p.A. 68 Stemline Therapeutics, Inc. 69 Sumitomo Dainippon Pharma Co., Ltd. 70 Synta Pharmaceuticals Corp. 71 Threshold Pharmaceuticals, Inc. 72 Vivolux AB 73 Refractory Multiple Myeloma - Therapeutics Assessment 74 Assessment by Monotherapy Products 74 Assessment by Combination Products 75 Assessment by Target 76 Assessment by Mechanism of Action 81 Assessment by Route of Administration 85 Assessment by Molecule Type 87 Drug Profiles 89 4SC-202 - Drug Profile 89 ABBV-838 - Drug Profile
3
91 ACP-196 - Drug Profile 92 ACY-241 - Drug Profile 95 afuresertib hydrochloride - Drug Profile 97 alisertib - Drug Profile 99 alpelisib - Drug Profile 103 ALT-801 - Drug Profile 105 ALT-803 - Drug Profile 108 amrubicin hydrochloride - Drug Profile 110 AR-42 - Drug Profile 112 AT-7519 - Drug Profile 114 AT-9283 - Drug Profile 117 B-701 - Drug Profile 119 bendamustine hydrochloride - Drug Profile 120 BI-836909 - Drug Profile 123 BMS-986016 - Drug Profile 124 cabozantinib s-malate - Drug Profile 125 carfilzomib - Drug Profile 129 CB-5083 - Drug Profile 133 CB-839 - Drug Profile 134 CC-90002 - Drug Profile 136 Cell Therapy to Target CD 138 for Relapsed and Refractory Multiple Myeloma - Drug Profile 137 CUDC-907 - Drug Profile 138 CWP-291 - Drug Profile 140 daratumumab - Drug Profile 142 DCRM-1711 - Drug Profile 145 DKN-01 - Drug Profile 147 elotuzumab - Drug Profile 149 erismodegib - Drug Profile 151 evofosfamide - Drug Profile 154 filanesib - Drug Profile 161 ganetespib - Drug Profile 163 GSK-2857916 - Drug Profile
4
167 I131-CLR1404 - Drug Profile 168 ibrutinib - Drug Profile 170 indatuximab ravtansine - Drug Profile 177 inebilizumab - Drug Profile 179 ipilimumab - Drug Profile 181 isatuximab - Drug Profile 185 ixazomib citrate - Drug Profile 187 JP-11646 - Drug Profile 191 LCL-161 - Drug Profile 192 linsitinib - Drug Profile 194 marizomib - Drug Profile 196 Melflufen - Drug Profile 198 milatuzumab - Drug Profile 200 MOR-202 - Drug Profile 202 MV-NIS - Drug Profile 204 NL-101 - Drug Profile 206 OPB-51602 - Drug Profile 207 oprozomib - Drug Profile 208 palbociclib - Drug Profile 210 PATSM-6 - Drug Profile 214 pelareorep - Drug Profile 216 pembrolizumab - Drug Profile 221 pidilizumab - Drug Profile 230 PIM-447 - Drug Profile 232 plerixafor - Drug Profile 233 plitidepsin - Drug Profile 235 PRLX-93936 - Drug Profile 237 Recombinant Protein for Oncology - Drug Profile 239 ricolinostat - Drug Profile 241 roneparstat - Drug Profile 243 RRX-001 - Drug Profile 244 sapanisertib - Drug Profile 246 selinexor - Drug Profile
5
248 SL-401 - Drug Profile 254 trametinib dimethyl sulfoxide + uprosertib - Drug Profile 256 ulocuplumab - Drug Profile 258 urelumab - Drug Profile 260 vemurafenib - Drug Profile 262 venetoclax - Drug Profile 266 VLX-1570 - Drug Profile 269 vorinostat - Drug Profile 271 Refractory Multiple Myeloma - Recent Pipeline Updates 275 Refractory Multiple Myeloma - Dormant Projects 443 Refractory Multiple Myeloma - Discontinued Products 447 Refractory Multiple Myeloma - Product Development Milestones 448 Featured News & Press Releases 448 Appendix 456 Methodology 456 Coverage 456 Secondary Research 456 Primary Research 456 Expert Panel Validation 456 Contact Us 456 Disclaimer Read More http://www.idatainsights.com/reports-landing-page.php?id=124191/refractory-multiple-myeloma-pipelinereview-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
Contact Us: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com
About iData Insights
6
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.
7